It is now over a decade since cyclic AMP and cyclic AMP-dependent protein kinases were shown to be involved in hormone-stimulated steroidogenesis (Catt & Dufau, 1973; Rommerts et al., 1974 ). Yet, to date the exact site(s) at which steroidogenesis is controlled and the mechanisms involved are still uncertain. Most of the data obtained suggest three possible sites: (i) the conversion of cholesterol esters to cholesterol in the lipid droplets, (ii) the transport of cholesterol from the lipid droplet to the inner mitochondrial membrane and (iii) the conversion of cholesterol to pregnenolone by the cholesterol side chain cleavage enzyme (see review by Simpson, 1979) . Recent studies have suggested that a calcium/ calmodulin system may control the transport of cholesterol from lipid droplets to the mitochondria (Hall et al., 1981) and the involvement of phosphatidylinositol metabolism/turnover in steroidogenesis has also been implicated (Farese et al., 1980) . In this report we present evidence which strongly suggests that products of the recently discovered lipoxygenase pathway of arachidonic acid metabolism (Borgeat & Samuelsson, 1979) may play an essential part in trophic hormonestimulated steroidogenesis.
It is established that non-steroidal anti-inflammatory drugs block the formation of prostaglandins by inhibiting the cyclo-oxygenase pathway of arachidonic acid metabolism (Ferreira & Vane, 1979) . Recently it has been shown that some of these non-steroidal anti-inflammatory compounds also inhibit the lipoxygenase pathway of arachidonic acid metabolism (Higgs et al., 1979; Walker & Dawson, 1980) . We have investigated the effects of two of these compounds, BW755C and benoxaprofen (Opren) on steroidogenesis. In addition, NDGA and ETYA, which are potent inhibitors of lipoxygenase activity, and two inhibitors of cyclo-oxygenase activity, indomethacin and aspirin (Ferreira et al., 1971 ) have been studied. The effect of inhibition of arachidonic acid metabolism by these compounds has been investigated by using Leydig cells purified from rat testes and from a Leydig cell tumour.
Materials and methods
Sheep LH (NIH-S20, 1.9 i.u. NIH-SI/mg) was a gift from the Endocrinology Study Section, National Institute of Health, Bethesda, MD, U.S.A. Hepes [4-(2-hydroxyethyl)-l -piperazineethanesulphonic acid], bovine serum albumin (fraction V), aspirin (2-acetoxybenzoic acid), indomethacin [1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-ylacetic acid) the calcium ionophore A23187 and NDGA were purchased from Sigma Chemical Co. BW 755C was a gift from Wellcome Research Laboratories (Beckenham, Kent, U.K.), ETYA (Ro 3-1428) was a gift from Hoffmann-La Roche Inc. (Nutley, NJ, U.S.A.) and benoxaprofen was a gift from Lilly Research Centre (Windlesham, Surrey, U.K.). Percoll was purchased from Pharmacia Fine Chemicals and 3-isobutyl-l-methylxanthine was purchased from Aldrich Chemical Co. Dulbecco's modified minimum essential media either with or without NaHCO3 were purchased from Gibco Biocult (Paisley, Scotland, U.K.). [1-14C]Arachidonic acid (58.4mCi/mmol) and [5,6,8,9,1,12,14,15(n) -3H]-leukotriene B4 (210Ci/mmol) were purchased from Amersham Intemational.
12-L- [5,6,8,9,11,12,14,15-3H(n) ]Hydroxy-5,8,10,14-eicosatetraenoic acid (48 Ci/mmol) and 5-L- [5,6,8,9,11,12,14,15-3H(n) ]Hydroxy-6,8,11,14-eicosatetraenoic acid (80 Ci/mmol) were purchased from New England Nuclear. All radiochemicals were stored under N2 at -21°C and used without further purification.
Cell isolation and purification
Leydig cells from rat testes were isolated and purified on 0-90% Percoll gradients as previously described (Hunter et al., 1982; . Leydig tumour cells used for this study have been characterized previously (Cooke et al., 1979) . The Leydig tumours were grown in Fischer rats and the cells isolated and purified using 0-90% Percoll gradients as previously described . Cells with an average density of 1.070g/ml were used in all studies.
Cell incubations
Purified rat testis or tumour Leydig cells were suspended in Dulbecco's minimum essential media containing 0.1% bovine serum albumin. When cyclic AMP was to be determined the media also contained the phosphodiesterase inhibitor, isobutylmethylxanthine (0.5mM). The cells (100000/well) were preincubated for 2h at 32°C in an atmosphere of air/CO2 (9:1) and then for a further 15 min with inhibitors of arachidonic acid metabolism followed by a 1 or 2 h incubation in the absence or presence of LH (100 ng/ml for testis Leydig cells and 1.0,ug/ml for tumour Leydig cells). Incubations were stopped by the addition of HC104 (final concentration 0.5M) and neutralized with K3PO4 (final concentration 0.23M). Testosterone, pregnenolone and cyclic AMP were determined by specific radioimmunoassay as previously described (Verjans et al., 1973; van der Vusse et al., 1975; Steiner et al., 1972; Harper & Brooker, 1975) . In experiments where pregnenolone production was determined cyanoketone (5 x 10-9M) and SU 10603 (2 x 10-8M) were also added to inhibit the metabolism of pregnenolone to testosterone. 
Statistical analysis
Statistical analysis was by Student's t-test.
Results
As can be seen in Fig. 1(a lb). NDGA and ETYA inhibited LH-stimulated cyclic AMP production over the same concentration range that inhibited testosterone production. However, if steroidogenesis was stimulated with dibutyryl cyclic AMP, NDGA and ETYA still inhibited testosterone production with similar potency to that seen with LH-stimulated steroidogenesis ( Fig. 2a and Table 1 ).
In order to investigate further the site of action of these inhibitors, experiments were performed in which the conversion of pregnenolone to testosterone by the Leydig cells was inhibited with SU 10603 (an inhibitor of 17fl-hydroxylase, EC 1.14.1.7) and cyanoketone (an inhibitor of 3,Bhydroxysteroid dehydrogenase, EC 1.1.1.51) and the dibutyryl cyclic AMP-stimulated production of pregnenolone was measured. Again NDGA (Fig.  2b ) produced a dose-related inhibition of pregnenolone production with a similar ID50 as seen for testosterone production (2-3 gM). BW 755C (75 guM) and benoxaprofen (70 pM) also inhibited pregnenolone production to 27 + 4.7 and 30 + 4.7%, respectively of the LH-stimulated pregnenolone production (190+24ng/106 cells per 2h). When pregnenolone was added to the Leydig cells its conversion to testosterone was not inhibited by NDGA using concentrations up to lOjm; with 1.25 uM-NDGA a significant increase (P < 0.001) in the conversion of pregnenolone to testosterone was found (Table 2) . Indomethacin again had no significant effect on this conversion at concentrations up to 100,lM. When (22R)-hydroxycholesterol was used instead of pregnenolone the results were essentially the same (Table 2) , again with the only significant effect being an increased conversion of (22R)-hydroxycholesterol to testosterone with 1.25 jM-NDGA (P < 0.05). The increased conversion of pregnenolone to testosterone was seen in a more detailed study with several concentrations of both NDGA and ETYA (Table  3 ). This increase was still evident when indomethacin (50juM) was present along with either NDGA or ETYA (results not shown). In order to study the possible production of lipoxygenase products by Leydig cells, the Leydig tumour was used since a large number of pure tumour cells can be obtained, which is essential for the detection of these metabolites of arachidonic acid. Tables 4 and 5 show the results of the effects of aspirin, indomethacin, BW 755C, benoxaprofen and NDGA on pregnenolone production in the purified rat tumour Leydig cells. These results are essentially the same as those for the rat testes Leydig cells. Both aspirin and indomethacin at concentrations up to 80 gM had no significant effect on LH-stimulated pregnenolone production (Table 4) , whereas both BW 755C and benoxaprofen produced a dosedependent inhibition (Table 4) Leydig cells were preincubated for 2 h in minimum essential medium + 0.1% bovine serum albumin and isobutylmethylxanthine (0.5 mM) and then incubated in the presence of various concentrations of (A) indomethacin, (0) benoxaprofen, (0) BW 755C, (El) NDGA and (-) ETYA for 15 min followed by a 2 h incubation in the presence of LH (lOOng/ml) at 32°C in an atmosphere of air/CO2 (9:1). (Table 5) .
When tumour Leydig cells were incubated with Rat Leydig cells were preincubated in minimum essential medium+0.l% bovine serum albumin for 2h and then incubated for 15min with various concentrations of NDGA followed by 2h incubation in the presence of dibutyryl cyclic AMP (2mM) at 32°C under an atmosphere of air/CO2 (9: r) and (a) testosterone and (b) pregnenolone production was determined as described in the Materials and methods section. When pregnenolone production was measured SU-10603 (2 x 10-8M) and cyanoketone (5 x 10-9M) were also present in the incubation media. Values represent means+S.D. of duplicate determinations on triplicate samples. reduced the amount of radioactive products in fractions 2, 3 and 4 (Fig. 3, lane 5 ) and in three comparable experiments the percentage reduction of these products was statistically significant (Table 6 ). BW755C and benoxaprofen also produced a similar pattern of inhibition of the arachidonic acid metabolites in these fractions (Table 6 ) while aspirin had similar inconsistent effects to indomethacin (Table 6 ). experiments in which the radioactivity was determined, summated and represented as a percentage of the total radioactivity as seen in Table 4 . Table 4 . Effect ofvarious inhibitors ofarachidonic acid metabolism on LH-stimulated pregnenolone production bypurified rat tumour Leydig cells Rat tumour Leydig cells were preincubated in minimum essential medium + 0.1% bovine serum albumin for 2 h and then for 15 min with various concentrations of aspirin, indomethacin, BW 755C or benoxaprofen followed by a 1 h incubation in the presence of LH (1 ig/ml) at 32°C under an atmosphere of air/CO2 (9: 1). Cyanoketone (5 x 10 -9M) and SU-10603 (2 x 10-8M) were added 30min before LH. Pregnenolone was determined by specific radioimmunoassay as described in the Materials and methods section. Values represent means + S.D. of duplicate determinations on triplicate samples. Basal pregnenolone production was 11.6 ± 2.4ng/106 cells per h (mean ± S.D., n = 3). Table 5 . Effect ofNDGA on dibutyryl cyclic AMP-stimulated pregnenolone production by purified rat tumour Leydig cells Rat tumour Leydig cells were preincubated in minimum essential medium+0.1% bovine serum albumin for 2 h and then for 15 min with various concentrations of NDGA followed by a 2h incubation in the presence of dibutyryl cyclic AMP (2mM) at 32°C under an atmosphere of air/CO2 (9:1). Cyanoketone (5 x 10-9M) and SU-10603 (2 x 10-8M) were added 30min before dibutyryl cyclic AMP. Pregnenolone was determined by specific radioimmunoassay as described in the In the present study it has been clearly demonstrated that inhibitors of lipoxygenase but not cyclo-oxygenase activity inhibit LH-and dibutyryl cyclic AMP-stimulated steroidogenesis in purified testis and tumour Leydig cells. It is doubtful if these inhibitions can be the result of non-specific toxic effects of these compounds since indomethacin and aspirin up to concentrations much in excess of their cyclo-oxygenase inhibitory activity have little effect upon steroidogenesis. Also, the site of inhibition of steroidogenesis by all four compounds studied, NDGA, ETYA, BW755C and benoxaprofen seems to be the same; after cyclic AMP production and before the conversion of cholesterol to pregnenolone. Furthermore, since NDGA and ETYA are not structurally related to BW 755C and benoxaprofen it seems unlikely that a general non-specific effect could be operating. The potency of inhibition of LH-stimulated steroidogenesis by NDGA, ETYA, BW755C and benoxaprofen is very similar to the known potencies of these compounds for inhibition of lipoxygenase activity in other cell systems (Walker & Dawson, 1979; Higgs et al., 1979) .. These findings, together with the observation that [14C]-arachidonic acid is metabolized to products whose formation are inhibited by NDGA, BW755C and benoxaprofen, but not by aspirin or indomethacin, and that the degree of metabolism of arachidonic acid to these products is further increased by the calcium ionophore A23187, strongly suggests that lipoxygenase products are involved in the stimulation of steroidogenesis.
It has been known for some time that calcium is required for hormone-stimulated steroidogenesis (Birmingham et al., 1953; Janszen et al., 1976) and that the requirement for calcium is primarily at a step before the conversion of cholesterol to pregnenolone (Hall et al., 1981) . The metabolism of arachidonic acid, particularly the release of arachidonic acid from membrane phospholipids by phospholipase A2, is considered to be a calcium-dependent mechanism (Craven et al., 1981) . Results known to have stimulatory activity on steroidogenesis (Veldhuis & Klase, 1982) . Phosphatidylinositol metabolism/turnover has been implicated in steroidogenesis (Farese et al., 1980 ) and this turnover is the possible mechanism of calcium entry into the cell (Michell, 1975) . It is interesting to speculate that the activation of arachidonic acid metabolism and the production of lipoxygenase products may be the link between phosphatidylinositol metabolism, calcium and steroidogenesis, and evidence from the present study would suggest that a lipoxygenase product of arachidonic acid metabolism stimulates the transport of cholesterol or cholesterol ester to the mitochondria. A role for lipoxygenase products in stimulussecretion coupling has also been implicated in the pancreatic ,B cell for the stimulation of insulin release by glucose and other agents (Metz et al., 1982) and in the release of LH by LH releasing hormone in pituitary gonadotrophins (Naor & Catt, 1981) . Lipoxygenase products may play a pivotal role in many stimulus-secretion coupling events in endocrine cells. However, in the present study we were unable to show a consistent or convincing effect of LH on arachidonic acid metabolism, which contrasts with the potent effects of the inhibitors on steroidogenesis. This may be because LH mobilizes large amounts of endogenous arachidonic acid from membrane stores, thus diluting the specific radioactivity of the exogenously applied arachidonic acid. Indeed, endogenous arachidonic acid may be metabolized in preference to the exogenous label, indicating that pre-incorporation of [14C]arachidonic acid may be necessary before conclusions can be drawn on the role of LH in these events.
An interesting result is the potentiation of the conversion of both pregnenolone and (22R)-hydroxycholesterol to testosterone by low concentrations of NDGA and ETYA. The reason for this is unclear. It is unlikely that selective inhibition of the lipoxygenase pathway leading to an increased production of products via the cyclo-oxygenase pathway could explain this potentiation, since indomethacin did not inhibit the potentiation seen with ETYA or NDGA. A selective inhibition of cyclo-oxygenase at low concentrations of these compounds may result in an increased production of lipoxygenase products and this may have a stimulatory action on one of the enzymes involved in the conversion of pregnenolone to testosterone. It is also possible that both ETYA and NDGA could have direct effects on one of the enzymes in the steroidogenic pathway. However, since the enzymes involved in the conversion of pregnenolone to testosterone are not rate-limiting for LHstimulated steroidogenesis this potentiation is of minor importance compared with the inhibiting actions of these compounds at early stages in the steroidogenic pathway.
In conclusion, we-have demonstrated for the first time that inhibitors of lipoxygenase activity, but not of cyclo-oxygenase activity, cause a potent inhibition of LH-and dibutyryl cyclic AMPstimulated steroidogenesis in rat Leydig cells. Preliminary evidence indicates that these inhibitors also inhibit products of arachidonic acid metabolism that have similar relative mobilities to those of reported lipoxygenase products of other systems. Our results indicate that lipoxygenase products may be essential for one of the steps before the conversion of cholesterol or cholesterol esters to pregnenolone. Since these steps are common to all steroidogenic pathways, such findings may be important in the control of steroidogenesis not only in the testis but also in the ovary and the adrenal gland.
